Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Developing potent HIV-specific CAR T cells through optimizing antigen sensitivity

Award Number: R01AI186810
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/07/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2029

Group Awards By:

View Award Description

Developing potent HIV-specific CAR T cells through optimizing antigen sensitivity - PROJECT SUMMARY Given the inability of the immune response to consistently suppress HIV without antiretroviral therapy and the insufficient potency of current cure approaches, genetic engineering modalities may offer a potent alternative to intrinsic immunity. Chimeric antigen receptor (CAR) T cells have shown impressive efficacy in eliminating blood cell cancers in the clinic, and CAR T cells re-engineered to target HIV using the CD4 ectodomain represent a potent escape-resistant cellular therapy demonstrated to have enhanced cytolytic function. Our prior work has demonstrated that when engineered to express both the 4-1BB and CD28 costimulatory domains and protected from HIV infection, HIV-specific CD4 ectodomain CAR T cells can reduce acute viremia, prevent CD4+ T cell loss, and reduce viral burden in the tissues of HIV-infected humanized mice. However, the of reduction plasma viral loads was ultimately transient, suggesting that the potency of HIV-specific CAR T cells should be further optimized for clinical translation. We propose that low expression of HIV Envelope (Env) on HIV-infected cells yields targets with low antigen density. Our preliminary data demonstrates that the potency of CD4 ectodomain CARs is severely attenuated in instances of low antigen density. We reason that this necessitates the design of HIV-specific CAR T cells with enhanced antigen sensitivity. As the characteristics dictating antigen sensitivity are not yet fully described for CAR T cells, we generated a diverse panel of broadly neutralizing antibody-based CAR T cells, specifically to (1) determine the relationship between epitope accessibility, CAR avidity, and antigen sensitivity on HIV-specific CAR T cell potency and (2) identify orthogonal CAR-driven escape patterns informing optimal multi-specificity CAR products that restrict HIV escape in vivo. The ultimate goal is to generate an enhanced HIV-specific CAR T cell product with the ability to kill HIV-infected cells expressing low levels of antigen in order to improve the translational potential of a CAR T cell approach for a functional HIV cure.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $558,595 )
2026	2026	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	3601 SPRUCE ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	000	3	5/19/2026	NON-COMPETING CONTINUATION	$558,595
														Subtotal = $558,595

Issue Date FY: 2025 ( Subtotal = $558,595 )
2025	2025	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	3601 SPRUCE ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	000	2	5/2/2025	NON-COMPETING CONTINUATION	$558,595
														Subtotal = $558,595

Issue Date FY: 2024 ( Subtotal = $558,595 )
2024	2024	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	3601 SPRUCE ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	001	1	9/3/2024	NEW	$55,858
2024	2024	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	3601 SPRUCE ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	000	1	6/7/2024	NEW	$502,737
														Subtotal = $558,595

Grand Total All Awards = $1,675,785

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Developing potent HIV-specific CAR T cells through optimizing antigen sensitivity

Award Number: R01AI186810

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/07/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer